Related Experiment Videos
Human immunodeficiency virus replication: modulation by cellular levels of cAMP
1Department of Internal Medicine, University of Texas Medical Branch, Galveston 77550.
AIDS Research and Human Retroviruses
|July 1, 1992
Summary
Elevated cyclic adenosine monophosphate (cAMP) levels boost HIV replication in immune cells. Inhibiting protein kinase A (PKA) significantly reduces viral activity, suggesting PKA as a potential anti-HIV therapy target.
Area of Science:
- Virology
- Immunology
- Molecular Biology
Background:
- HIV infection causes immune deficiencies.
- HIV infection in CD4+ cells is linked to elevated cAMP and cGMP.
- The specific role of cAMP in HIV replication requires further investigation.
Purpose of the Study:
- To investigate the role of cyclic adenosine monophosphate (cAMP) in HIV replication.
- To determine if protein kinase A (PKA) mediates cAMP's effect on HIV replication.
- To explore PKA as a potential target for anti-HIV therapies.
Main Methods:
- MT-4 cells were infected with HIV (strain 3b).
- Agents increasing intracellular cAMP (Forskolin, IBMX, dibutyryl cAMP) were used.
- HIV replication was measured by reverse transcriptase activity and HIV P24Ag.
- Intracellular cAMP levels were quantified using radioimmunoassay.
- The effect of H-8, a PKA inhibitor, on HIV replication was assessed.
Main Results:
- Forskolin, IBMX, and dibutyryl cAMP dose-dependently enhanced HIV replication (2- to 10-fold).
- Intracellular cAMP levels were significantly elevated by these agents.
- H-8 inhibited HIV replication in MT-4 cells (25-99.9%) and peripheral blood mononuclear cells (>90%).
Conclusions:
- HIV replication is dependent on cyclic adenosine monophosphate (cAMP).
- Protein kinase A (PKA) plays a crucial role in mediating cAMP's effect on HIV replication.
- PKA inhibition demonstrates potential for developing novel anti-HIV therapies.